CytomX Therapeutics to Present at Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in virtual fireside chats at the following investor conferences in November.

12th Annual Jefferies Global Healthcare ConferenceDate: Thursday, November 18, 2021

33rd Annual Piper Sandler Virtual Healthcare ConferenceDate: Tuesday, November 30, 2021

The Jefferies fireside chat will be made available at 3:00 a.m. ET (8:00 a.m. GMT) on Thursday, November 18, 2021 on the Events and Presentations page of CytomX’s website at www.cytomx.com. The Piper Sandler fireside chat will be made available at 10:00 a.m. ET on Monday, November 22, 2021. Archived replays of both fireside chats will be available on the CytomX website for 30 days following the event. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments and successfully leverage therapeutic targets that were once thought to be inaccessible. CytomX’s robust and differentiated pipeline includes the wholly-owned praluzatamab ravtansine (CX-2009), an investigational conditionally activated antibody-drug conjugate (ADC) directed toward CD166, and CX-2029, an investigational conditionally activated ADC directed toward CD71 co-developed with AbbVie. These two programs are currently being evaluated in Phase 2 studies, targeting a variety of late-stage, difficult-to-treat cancer types, including breast cancer for praluzatamab ravtansine, and squamous non-small cell lung cancer, and head and neck squamous cell carcinoma for CX-2029. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab (CX-072). In addition, CytomX has a diverse preclinical portfolio and strategic collaborations with other leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and Twitter.

Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

Investor Contact:Chau Cheng, PhD MBAVP, Investor Relations & Corp. Communications[email protected]Direct: (650) 273-4999

Media Contact:Bret CoonsDirector, Corporate Communications[email protected]Direct: (650) 528 2929

You May Also Be Interested In

• Solana Unchained Emerges as a Closely Watched Solana Presale Following Product Ecosystem Reveal
• BNP PARIBAS GROUP: SUDAN LITIGATION STATEMENT FROM BNP PARIBAS
• Zcash Price Prediction: ZEC Eyes $1,000 After 48% Surge as AlphaPepe Emerges in the Top AI Crypto Coin Race